Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Harvard And Merck Form Research Pact
April 14, 2008
| A version of this story appeared in
Volume 86, Issue 15
Harvard University's Office of Technology Development has signed a multiyear license and sponsored-research agreement with Merck & Co. focused on new osteoporosis therapies. Merck will fund research in the lab of immunology professor Laurie Glimcher. In return, it will get licenses to specific molecules that may result from the work. Glimcher studies the molecular pathways that lead to bone growth and looks for intervention points for enhancing bone formation or preventing osteoporosis in adults. Her lab has already identified several key mediators of bone growth that Merck hopes to use in the development of therapies.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter